SCHEMBL678943

SCHEMBL678943

C=C(N)c1ccc(Cn2nc3c(c2Sc2ccccc2)c(=O)n(C)c(=O)n3C2CCCC2)cc1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.35
PDE1B Q01064 3/20 0.34
PDE1A P54750 1/20 0.34
PDE1C Q14123 1/20 0.34
TSHR P16473 3/20 0.33
TP53 P04637 2/20 0.33
PIK3CA P42336 1/20 0.33
PRKDC P78527 1/20 0.33
MAPK1 P28482 1/20 0.33
HSD17B10 Q99714 1/20 0.33
AURKA O14965 3/20 0.32
AURKB Q96GD4 3/20 0.32
ALDH1A1 P00352 1/20 0.32
DPP4 P27487 1/20 0.32
CRHBP P24387 3/20 0.32
CRHR2 Q13324 3/20 0.32
NPSR1 Q6W5P4 2/20 0.32
MEN1 O00255 1/20 0.32
KMT2A Q03164 1/20 0.32
DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15943411 0.92 HRH3 (0.36) PDE4APDE1BPDE1APDE1CTP53
SCHEMBL679839 0.83 PRKDC (0.35) PDE4APDE1BPDE1APDE1CTSHR
SCHEMBL15943433 0.82 PDE4A (0.39) PDE4APDE1BPDE1APDE1CTSHR
SCHEMBL2612355 0.75 PDE1B (0.32) PDE4APDE1BPDE1APDE1CTSHR
SCHEMBL676517 0.69 PDE1B (0.54) PDE4APDE1BPDE1APDE1CTSHR
SCHEMBL674429 0.69 ALDH1A1 (0.43) MAPK1ALDH1A1SMN1; SMN2LMNATHRB
SCHEMBL15943450 0.68 PDE1B (0.45) PDE1BPDE1APDE1C
SCHEMBL9608324 0.68 ALDH1A1 (0.34) PDE4APDE1BPDE1APDE1CTSHR
SCHEMBL679944 0.67 PDE1B (0.47) PDE1BPDE1APDE1CMEN1KMT2A
SCHEMBL678927 0.67 PDE1B (0.44) PDE1BPDE1APDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9487527-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase I INTRA-CELLULAR THERAPIES, INC. (US) 2016-11-08 US disclosed
US-20150119370-A1 Organic Compounds LI PENG (US) 2015-04-30 US disclosed
US-8859564-B2 Pyrazolo[3,4-d]pyrimidine-4,6(5H,7H)-dione derivatives useful as inhibitors of phosphodiesterase 1 INTRA-CELLULAR THERAPIES, INC. (US) 2014-10-14 US disclosed
US-20110281832-A1 ORGANIC COMPOUNDS INTRA-CELLULAR THERAPIES, INC. 2011-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110281832-A1 ORGANIC COMPOUNDS CYP2C9, CYP2C19, CYP3A4 PDE4A 1439/4885PDE1B 4855/4885PDE1A 4874/4885
US-20150119370-A1 Organic Compounds CYP2C19, CYP2C9, CYP3A43 PDE4A 3195/4885PDE1B 4882/4885PDE1A 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.